Vancouver, Canada — November 13, 2025 — Leads & Copy — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0), a clinical-stage biotech company, has received final approval from Hadassah Medical Center in Jerusalem, Israel, for its Phase 1/2a clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD).
The approval enables Hadassah Medical Center, a leading clinical site in Israel, to participate in the company’s clinical trial, which successfully completed its first cohort treatment. Other institutions involved in the trial include Yale School of Medicine’s Department of Psychiatry, Johns Hopkins University School of Medicine, and Tel Aviv Sourasky Medical Center in Israel.
Professor Joseph Caraco, Director of Clinical Pharmacology Unit in the Department of Medicine, will lead the study at Hadassah-University Medical Center.
According to the World Health Organization, AUD accounts for 4.7% of deaths worldwide, Clearmind’s clinical trial marks a step in addressing AUD’s global impact. The company anticipates progress in patient enrollment and data collection, aiming to deliver a breakthrough solution for those affected by AUD and their families.
The Phase 1/2a clinical trial is a multinational, multi-center study designed to assess the safety, tolerability, and pharmacokinetic profile of CMND-100. It will also evaluate the drug’s preliminary efficacy in reducing alcohol cravings and consumption in patients with AUD.
Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical biotech company focused on discovering and developing novel psychedelic-derived therapeutics for widespread and underserved health problems, including alcohol use disorder. Clearmind intends to commercialize psychedelic-based compounds as regulated medicines, foods, or supplements.
The company’s intellectual portfolio consists of nineteen patent families, including 31 granted patents and intends to seek additional patents for its compounds and remain opportunistic regarding acquiring additional intellectual property.
Shares of Clearmind are listed on Nasdaq under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol “CWY0.”
Investor Relations:
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries:
Info@Clearmindmedicine.com
Source: Clearmind Medicine Inc.
Source: Clearmind Medicine Inc.
